Background
cancers, tumor, bone sarcomas, chemotherapy-refractory, undifferentiated pleomorphic sarcoma, cancer, cancers of bone and soft tissue, soft-tissue sarcoma, Sarcomas, soft-tissue sarcomas
CANCERS, TUMOR, BONE SARCOMAS, CANCER, SOLID TUMORS, UNDIFFERENTIATED PLEOMORPHIC SARCOMA, SARCOMAS, DEDIFFERENTIATED LIPOSARCOMA
Sarcomas are a rare and heterogeneous group of cancers of bone and soft tissue that originate from mesenchymal cells [Immune checkpoint inhibitors (ICIs) have demonstrated remarkable clinical outcomes in many chemotherapy-refractory solid cancers. But ICI monotherapy only showed promising anti-tumor activity in certain histologic types of soft-tissue sarcomas, with an ORR of 23% in undifferentiated pleomorphic sarcoma and 10% in dedifferentiated liposarcoma, whereas only 5% of patients with bone sarcomas achieved an objective response [Cell-based immunotherapy uses a cell type from the immune system as therapeutic agent, such as tumor specific T cells, natural killer cells, and dendritic cells (DCs). The cells are removed from the body and then re-infused into the patient after activation or modification, having the potential to rescue the destroyed immune system and enhance the function of ICIs. Considering the interaction between immunosuppression and angiogenesis in tumor development, addition of ICIs and cell-based immunotherapeutic agents to angiogenesis-targeted agents may constitute a new effective treatment strategy in bone and soft-tissue sarcoma.Multiple antigen-stimulating cell therapy-I (MASCT-I) technology is a sequential immune cell therapy for cancer, the first application to combine DC vaccine and adoptive T cell transfer in one treatment course. It composes of 15 tumor associated antigens loaded DC vaccine and adoptive cellular therapy, which can trigger both active and passive immune response. Previous studies showed that MASCT-I alone or in combination with apatinib (a highly selective TKI targeting vascular endothelial growth factor receptor 2 [VEGFR2]) exhibited clinical benefit and manageable safety profile in patients with advanced solid tumors refractory or intolerant to standard therapy [